12:00 AM
 | 
Aug 05, 2013
 |  BC Week In Review  |  Company News  |  Deals

PharmAthene, Theraclone deal

Biodefense company PharmAthene and antibody company Theraclone will merge in a stock deal, which is expected to close next quarter. PharmAthene will be the surviving entity. Theraclone will own 50% of the surviving entity. Theraclone's CEO Clifford Stocks will become president and CEO of the entity, and PharmAthene's CEO Eric Richman will become a director. Both of the company's boards approved the merger, which is subject to shareholder approval. The companies declined to provide Theraclone's valuation. PharmAthene had $12.9 million in cash as of March 30 and an operating loss of $6.3 million in 2012. Leerink Swann was financial advisor to PharmAthene. Healthios Capital Markets was financial advisor to Theraclone.

The combined company's pipeline will include...

Read the full 565 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >